Ocular Therapeutix will present research on retinal therapies at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting.
Quiver AI Summary
Ocular Therapeutix, Inc. has announced its participation in the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting, scheduled for February 8, 2025, where it will present new findings related to its product candidate AXPAXLI™ (OTX-TKI) and its application in treating retinal diseases. Notable presentations include the results from the Phase 1 to Phase 3 trials for neovascular age-related macular degeneration (AMD) and findings from a clinical trial focused on non-proliferative diabetic retinopathy. Ocular is utilizing its proprietary bioresorbable hydrogel technology, ELUTYX™, in its ongoing trials, which highlights the company's commitment to advancing treatment options in the retinal disease space. The conference presentations will feature insights from expert physicians, furthering the dialogue on emerging therapies for these conditions.
Potential Positives
- Ocular Therapeutix is showcasing significant advancements in its research with multiple presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting, highlighting its commitment to innovation in retinal therapies.
- The company’s lead product candidate AXPAXLI (OTX-TKI) is currently in Phase 3 clinical trials for wet age-related macular degeneration (AMD), indicating a progression towards potential market introduction.
- Ocular Therapeutix is leveraging its proprietary ELUTYX technology in both its clinical pipeline and existing commercial products, reinforcing its unique position in the biopharmaceutical sector focused on ocular diseases.
Potential Negatives
- The press release focuses heavily on the presentation of specific trials, which may suggest a lack of significant recent advancements or results, potentially signaling stagnation in the company's development pipeline.
- Despite the upcoming presentations, there is no new product approval or major milestone announcement, which could create a perception of limited progress within the company.
- The mention of specific presentation sessions but lack of detailed outcomes or data may raise concerns among investors or stakeholders regarding the effectiveness or viability of the ongoing clinical trials.
FAQ
What is Ocular Therapeutix, Inc. known for?
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on redefining the retina experience through innovative treatments.
When are the upcoming presentations at the Angiogenesis 2025 conference?
The presentations are scheduled for February 8, 2025, at the Angiogenesis, Exudation, and Degeneration virtual meeting.
What are the key studies being presented by Ocular Therapeutix?
Key studies include Phase 1 to Phase 3 results of OTX-TKI for neovascular AMD and findings on diabetic retinopathy.
Who will be presenting at the Angiogenesis 2025 meeting?
Presenters include Carl J. Danzig, MD, Mark R. Barakat, MD, and Justis P. Ehlers, MD.
What technology underpins Ocular's product candidate AXPAXLI?
AXPAXLI is based on Ocular's ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 2 sales selling 41,560 shares for an estimated $374,664.
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 2 sales selling 3,646 shares for an estimated $32,850.
- JEFFREY S. HEIER (Chief Scientific Officer) sold 2,948 shares for an estimated $26,561
- PETER KAISER (Chief Development Officer) sold 2,897 shares for an estimated $26,101
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OCUL Hedge Fund Activity
We have seen 74 institutional investors add shares of $OCUL stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. removed 2,825,756 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $24,131,956
- LOGOS GLOBAL MANAGEMENT LP removed 1,650,000 shares (-32.0%) from their portfolio in Q3 2024, for an estimated $14,354,999
- ACUTA CAPITAL PARTNERS, LLC removed 1,581,059 shares (-57.1%) from their portfolio in Q3 2024, for an estimated $13,755,213
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,056,092 shares (+inf%) to their portfolio in Q3 2024, for an estimated $9,188,000
- WOODLINE PARTNERS LP added 1,000,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $8,700,000
- INVESCO LTD. added 709,573 shares (+1545.9%) to their portfolio in Q3 2024, for an estimated $6,173,285
- POINT72 ASSET MANAGEMENT, L.P. removed 666,043 shares (-24.6%) from their portfolio in Q3 2024, for an estimated $5,794,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.
Presentation Details :
-
OTX-TKI From Phase 1 to Phase 3: SOL-1 and SOL-R Trials for Neovascular AMD
Session: V: Imaging and Emerging Therapies for Exudative AMD
Presentation Time: 2:30 PM ET
Presenter: Carl J. Danzig, MD
-
Phase 1 Results from Intravitreal Axitinib Implant (OTX-TKI) for the Treatment of Non-Proliferative Diabetic Retinopathy
Session: VII: Diabetic Retinopathy and Retinal Vascular Diseases
Presentation Time: 5:20 PM ET
Presenter: Mark R. Barakat, MD
-
Volumetric Macular Fluid Analysis of the Impact of a Single Axitinib Intravitreal Implant (OTX-TKI) from the HELIOS Clinical Trial for Diabetic Retinopathy
Session: VII: Diabetic Retinopathy and Retinal Vascular Diseases
Presentation Time: 5:25 PM ET
Presenter: Justis P. Ehlers, MD
Exact presentation times are subject to change. Expected presentation times can be found on the Program section of the Angiogenesis, Exudation, and Degeneration 2025 conference website .
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA ® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]
